Carisma Therapeutics Forecast, price target & analysts
Carisma Therapeutics Target price 2025 - Analyst rating & recommendation
Carisma Therapeutics Classifications & Recommendation:
Carisma Therapeutics Price Target
| Target Price | $1.00 |
| Price | $0.18 |
| Potential |
446.15%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Carisma Therapeutics price target 2026.
The average Carisma Therapeutics target price is $1.00.
This is
446.15%
register free of charge
|
|
| A rating was issued by 2 analysts: 1 Analysts recommend Carisma Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Carisma Therapeutics stock has an average upside potential 2026 of
446.15%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 19.63 | 17.50 |
| 31.57% | 10.85% | |
| Net Margin | -310.82% | -145.67% |
| 57.15% | 53.13% |
2 Analysts have issued a sales forecast Carisma Therapeutics 2025 . The average Carisma Therapeutics sales estimate is
This results in the following potential growth metrics:
2 Carisma Therapeutics Analysts have issued a net profit forecast 2025. The average Carisma Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2024 | -310.82% | 57.15% |
|---|---|---|
| 2025 |
-145.67%
53.13%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.46 | -0.61 |
| 43.63% | 58.22% | |
| P/E | negative | |
| EV/Sales | 0.13 |
2 Analysts have issued a Carisma Therapeutics forecast for earnings per share. The average Carisma Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Carisma Therapeutics stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 0.11 | 82.54% |
|---|---|---|
| 2025 |
0.13
16.36%
Unlock
|
|
P/S ratio
| Current | 0.38 | 90.14% |
|---|---|---|
| 2025 |
0.44
14.04%
Unlock
|
|
Carisma Therapeutics...
Current Carisma Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 17 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Baird |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 17 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
Baird:
Locked
➜
Locked
|
Dec 12 2024 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Dec 12 2024 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Dec 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
